BostonGene Secures Seven Abstracts at 2024 ASCO Annual Meeting

WALTHAM, Mass.-- BostonGene, a prominent entity in the realm of AI-driven molecular and immune profiling solutions, is set to present its ground-breaking research at the forthcoming 2024 ASCO Annual Meeting, scheduled from May 31 to June 3 at McCormick Place Convention Center in Chicago, IL. The company will present seven abstracts, including one oral presentation, two poster sessions, and four online-only abstracts. BostonGene will also have an exhibition booth at the event.

Key Highlights of BostonGene’s Participation:
BostonGene will prominently feature its AI-enhanced multiomics platform. This sophisticated platform accelerates research and drug development and facilitates precise matching of patients with the most suitable therapies.

Additionally, BostonGene will introduce its novel immune system profiling platform. This innovative platform classifies patients based on their responses to various cancer treatments, utilizing a scoring system to evaluate systemic immunity. The potential of this framework is underscored by a simple blood test, pending further clinical validation, to effectively categorize patients as responders or non-responders to treatments.

Details of Presentations:

Oral Presentation:
- Abstract: 2015
- Title: A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma
- Date and Time: Sunday, June 2, 2024, from 11:30 AM to 1:00 PM
- Speaker: Dr. Jiayi Huang, Washington University School of Medicine
This study investigated the immunological impact of combining avelumab, an anti-PD-L1 inhibitor, with radiation therapy for meningioma patients experiencing recurrence post-radiation. The findings, involving RNA-seq and MxIF analysis of pre- and post-treatment tumor tissues, revealed that this combination could induce an immune response leading to prolonged remission in some patients. This calls for further prospective studies and biomarker investigations.

Poster Presentations:
1. Abstract: 11523
- Title: Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas
- Date and Time: Saturday, June 1, 2024, from 1:30 PM to 4:30 PM
- Poster: 449
- Speaker: Nikita Kotlov, BostonGene
Through transcriptomic analysis, unique gene fusions in bone sarcomas were identified, emphasizing the role of RNA-seq in advancing sarcoma research and identifying potential biomarkers.

2. Abstract: 1044
- Title: The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast
- Date and Time: Sunday, June 2, 2024, from 9:00 AM to 12:00 PM
- Poster: 22
- Speaker: Dr. Jason Mouabbi, MD Anderson Cancer Center
Using integrated RNA-seq and MxIF, this study explored the complexity of the tumor microenvironment in invasive lobular carcinoma, highlighting the importance of detailed profiling for developing personalized treatments.

Online-Only Abstracts:
1. Abstract: e13168
- Title: Closing classification gaps in luminal breast cancer with single-cell RNA-seq insights from normal breast lineages
This study utilized single-cell RNA-seq to bridge gaps in luminal breast cancer classification, revealing complexities not captured by traditional methods.

2. Abstract: e15138
- Title: Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making
By combining whole exome and RNA sequencing, unique molecular features were identified in neuroendocrine tumors, suggesting comprehensive profiling can aid in treatment decisions.

3. Abstract: e13593
- Title: An unsupervised H&E-based machine-learning approach for precise prediction of tumor microenvironment subtypes
This study developed an H&E-based machine-learning method to predict tumor microenvironment subtypes in colorectal cancer, complementing next-generation sequencing classifications.

4. Abstract: e15086
- Title: Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer
Investigating the CCNG1 inhibitor DeltaRex-G alone or with DeltaRex-G Plus in advanced cancers revealed potential therapeutic benefits, warranting further research.

BostonGene continues to push the boundaries of cancer research. By leveraging AI and multiomics, BostonGene aims to enhance patient care, offering precision therapies and advancing cancer treatment research.

About BostonGene Corporation:
Founded in 2015, BostonGene focuses on the intersection of technology and biology to personalize and advance cancer treatment. Their AI-driven multiomics platform enables comprehensive molecular profiling, aiding in the discovery of treatment signatures, potential targets, and the development of effective therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!